A 2-year, phase IV, multicentre, observational study of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration in routine clinical practice: The EPICOHORT study

Journal of Ophthalmology

Volumn 2014, Issue , 2014, Pages

  Pagliarini, Sergio ^a   Beatty, Stephen ^b   Lipkova, Blandina ^c   Perez Salvador Garcia, Eduardo ^d   Reynders, Stefaan ^e   Gekkieva, Margarita ^f   Si Bouazza, Abdelkader ^f   Pilz, Stefan ^f  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b Institute of Eye Surgery and Macular Pigment Research Group Whitfield Eye Clinic   (Ireland)

^c FACULTY HOSPITAL   (Slovakia)

^d Hospital Divino Valles   (Spain)

^e Oogcentrum Oostende   (Belgium)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901284577     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2014/857148     Document Type: Article

References (23)

1. Lowe J., Araujo J., Yang J., Reich M., Oldendorp A., Shiu V., Quarmby V., Lowman H., Lien S., Gaudreault J., Maia M., Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Experimental Eye Research 2007 85 4 425 430 2-s2.0-35148885811 10.1016/j.exer.2007.05.008 (Pubitemid 47542265)
2. Abraham P., Yue H., Wilson L., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. American Journal of Ophthalmology 2010 150 3 315 324 2-s2.0-77956056292 10.1016/j.ajo.2010.04.011
3. Boyer D. S., Heier J. S., Brown D. M., Francom S. F., Ianchulev T., Rubio R. G., A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration. Ophthalmology 2009 116 9 1731 1739 2-s2.0-69249222585 10.1016/j.ophtha.2009.05.024
4. Brown D. M., Michels M., Kaiser P. K., Heier J. S., Sy J. P., Ianchulev T., Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. Ophthalmology 2009 116 1 57 65 2-s2.0-57949094834 10.1016/j.ophtha.2008.10.018
5. Holz F. G., Amoaku W., Donate J., Guymer R. H., Kellner U., Schlingemann R. O., Weichselberger A., Staurenghi G., Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology 2011 118 4 663 671 2-s2.0-79953295148 10.1016/j.ophtha.2010.12.019
6. Kaiser P. K., Boyer D. S., Cruess A. F., Slakter J. S., Pilz S., Weisberger A., Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study. Ophthalmology 2012 119 5 1001 1010 2-s2.0-84860450956 10.1016/j.ophtha.2012.02. 003
7. Kwon O.-W., Lee F. L., Chung H., Lai C.-C., Sheu S.-J., Yoon Y.-H., EXTEND III: Efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD. Graefe's Archive for Clinical and Experimental Ophthalmology 2012 250 10 1467 1476 2-s2.0-84857489133 10.1007/s00417-012-1970-3
8. Larsen M., Schmidt-Erfurth U., Lanzetta P., Wolf S., Simader C., Tokaji E., Pilz S., Weisberger A., Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results. Ophthalmology 2012 119 5 992 1000 2-s2.0-84860452217 10.1016/j.ophtha.2012.02.002
9. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1419 1431 2-s2.0-33749445317 10.1056/NEJMoa054481 (Pubitemid 44511557)
10. Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J.-F., Schlingemann R. O., Axer-Siegel R., Wiedemann P., Simader C., Gekkieva M., Weichselberger A., Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE Study. Ophthalmology 2011 118 5 831 839 2-s2.0-79955631484 10.1016/j.ophtha.2010.09.004
11. Tano Y., Ohji M., Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmologica 2011 89 3 208 217 2-s2.0-79955043800 10.1111/j.1755-3768.2010.02065.x
12. Silva R., Axer-Siegel R., Eldem B., The SECURE Study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 2013 120 1 130 139
13. Singer M. A., Awh C. C., Sadda S., Freeman W. R., Antoszyk A. N., Wong P., Tuomi L., HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012 119 6 1175 1183 2-s2.0-84856462182 10.1016/j.ophtha.2011.12. 016
14. Cohen S. Y., Dubois L., Tadayoni R., Fajnkuchen F., Nghiem-Buffet S., Delahaye-Mazza C., Guiberteau B., Quentel G., Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. American Journal of Ophthalmology 2009 148 3 409 413 2-s2.0-68949120732 10.1016/j.ajo.2009.04.001
15. Rothenbuehler S. P., Waeber D., Brinkmann C. K., Wolf S., Wolf-Schnurrbusch U. E. K., Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. American Journal of Ophthalmology 2009 147 5 831 837 2-s2.0-64649096877 10.1016/j.ajo.2008.12.005
16. Kumar A., Sahni J. N., Stangos A. N., Campa C., Harding S. P., Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. British Journal of Ophthalmology 2011 95 4 530 533 2-s2.0-79952992311 10.1136/bjo.2009.171868
17. Finger R. P., Wiedemann P., Blumhagen F., Pohland K., Holz F. G., Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study-A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmology 2012 91 6 540 546
18. Hjelmqvist L., Lindberg C., Kanulf P., Dahlgren H., Johanssonand I., Siewert A., One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. Journal of Ophthalmology 2011 2011 8 405724 10.1155/2011/405724
19. Holz F. G., Bandello F., Gillies M., Mitchell P., Osborne A., Sheidow T., Souiedand E., Figueroa M. S., Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS program. British Journal of Ophthalmology 2013 97 9 1161 1167 10.1136/bjophthalmol-2013-303232
20. Rakic J. M., Leys A., Brie J., Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS Study. Clinical Ophthalmology 2013 2013 7 1849 1858
21. Busbee B. G., Ho A. C., Brown D. M., Jeier J. S., Suner I. J., Li Z., Rubioand R. G., Lai P., Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013 120 5 1046 1056
22. Chakravarthy U., Harding S. P., Rogers C. A., Downes S. M., Lotery A. J., Wordsworth S., Reeves B. C., Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012 119 7 1399 1411
23. Martin D. F., Maguire M. G., Fine S. L., Ying G. S., Jaffe G. J., Grunwald J. E., Toth C., Redfordand M., Ferris F. L., Comparison of age-related Macular Degeneration Treatments Trials (CATT) research group. Ophthalmology 2012 119 7 1388 1398